Paddling furiously, to go backwards!
A popular AIM company covered here is struggling to make a return on substantial revenue – it could be an interesting recovery play, but significant and regularly recurring exceptional costs are also a concern to us. There was better news elsewhere, with upgrades for a software group and another important approval for a highly rated provider of infection prevention products. (Premium)
Tristel receives another approval Tristel (AIM: TSTL), the manufacturer of infection prevention products utilising its proprietary chlorine dioxide technology, has announced that Health Canada has approved Tristel ULT as a Class II Medical Device for endocavity ultrasound probes and skin surface transducers. The timing of this regulatory approval comes well ahead of the Company's original aim for gaining approval and allows commercial launch during FY 2024. The Health Canada approval, alongside the earlier approval from the US FDA means that the Tristel ULT can now be manufactured and sold throughout the whole of North America by Tristel's commercial partner Parker…